The results revealed that the majority of the patients with HER2-negative/ER-low-positive BC had a recurrence score (RS) > 25, and the authors concluded that perhaps genomic tests are of limited use as most patients are likely to benefit from adjuvant chemotherapy [45]. Here, ESR1 is linked to breast cancer.